ADMA Biologics Advances Plasma Collection Center Expansion Plans with Opening of New Facility in Myrtle Beach, SC

NEXT STORY
Clearside Biomedical Features FDA-Approved XIPERE™ in Multiple Presentations at the American Academy of Ophthalmology 2021 and American Uveitis Society Meetings
PREV STORY
Codiak Reports Positive Initial Data for exoSTING™ Phase 1/2 Trial Indicating Tolerability, Immune Activation, and Evidence of Tumor Shrinkage in Injected and Non-Injected Tumors in the First Three Dose Escalation Cohorts
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Quotient Limited Provides Fourth Quarter and Full Year Fiscal 2021 Results and provides Business Update

author_avatar
NASDAQ Market News

SAB Biotherapeutics Added to NASDAQ Biotechnology Index

author_avatar
NASDAQ Market News

Novartis Phase III CANTOS study demonstrates that targeting inflammation with ACZ885 reduces cardiovascular risk

Study showed a significant 15% reduction of major adverse cardiovascular events (MACE) in people ...

author_avatar
NASDAQ Market News